Efficacy and safety of direct‐acting antivirals for hepatitis C in the elderly: A systematic review and meta‐analysis

2019 ◽  
Vol 39 (9) ◽  
pp. 1652-1660 ◽  
Author(s):  
Marcus M. Mücke ◽  
Eva Herrmann ◽  
Victoria T. Mücke ◽  
Christiana Graf ◽  
Stefan Zeuzem ◽  
...  
Keyword(s):  
Systematic Review ◽  
Hepatitis C ◽  
Meta Analysis ◽  
The Elderly ◽  
Efficacy And Safety ◽  
Direct Acting Antivirals ◽  
Direct Acting

THU-163-Efficacy and safety of direct-acting antivirals for hepatitis C in elderly patients: a systematic review and meta-analysis

2019 ◽  
Vol 70 (1) ◽  
pp. e233-e234
Author(s):  
Marcus Mücke ◽  
Eva Herrmann ◽  
Victoria Therese Mücke ◽  
Christiana Graf ◽  
Stefan Zeuzem ◽  
...  
Keyword(s):  
Systematic Review ◽  
Hepatitis C ◽  
Elderly Patients ◽  
Meta Analysis ◽  
Efficacy And Safety ◽  
Direct Acting Antivirals ◽  
Direct Acting

scholarly journals Effectiveness of implementing a decentralized delivery of hepatitis C virus treatment with direct-acting antivirals: A systematic review with meta-analysis

PLoS ONE ◽  
2020 ◽  
Vol 15 (2) ◽  
pp. e0229143 ◽  
Author(s):  
Rodolfo Castro ◽  
Hugo Perazzo ◽  
Letícia Artilles Mello Mendonça de Araujo ◽  
Isabella Gonçalves Gutierres ◽  
Beatriz Grinsztejn ◽  
...  
Keyword(s):  
Systematic Review ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Meta Analysis ◽  
Direct Acting Antivirals ◽  
Direct Acting

Can Ribavirin be Avoided in the Management of Hepatitis C Genotype 3 Patients When Treated With Direct Acting Antivirals? A Systematic Review and Meta-Analysis

2017 ◽  
Vol 112 ◽  
pp. S559
Author(s):  
Muhammad Ali Khan ◽  
George Cholankeril ◽  
Chiranjeevi Gadiparthi ◽  
Mohammad Siddiqui ◽  
Khwaja F. Haq ◽  
...  
Keyword(s):  
Systematic Review ◽  
Hepatitis C ◽  
Meta Analysis ◽  
Direct Acting Antivirals ◽  
Genotype 3 ◽  
Direct Acting

scholarly journals Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Therapy with Direct-Acting Antivirals. A Systematic Review and Meta-Analysis

2021 ◽  
Vol 10 (8) ◽  
pp. 1694
Author(s):  
Leonardo Frazzoni ◽  
Usama Sikandar ◽  
Flavio Metelli ◽  
Sinan Sadalla ◽  
Giuseppe Mazzella ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Systematic Review ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Meta Analysis ◽  
Random Effect ◽  
Complete Response ◽  
Direct Acting Antivirals ◽  
Direct Acting ◽  
Hcc Recurrence

Background: Hepatocellular carcinoma (HCC) is a major cause of morbidity and mortality among patients with cirrhosis. The risk of HCC recurrence after a complete response among patients treated with direct-acting antivirals (DAAs) has not been fully elucidated yet. Aim: To assess the risk of HCC recurrence after DAA therapy for hepatitis C virus (HCV). Methods: A systematic review across PubMed, Scopus and Scholar up to November 2020, including full-text studies that assessed the pattern of HCC recurrence after DAA therapy for HCV. Random-effect meta-analysis and univariable metaregression were applied to obtain pooled estimates for proportions and relative risk (RR) and variables influential for the outcome, respectively. Results: Thirty-one studies with 2957 patients were included. Overall, 30% (CI, 26–34%) of the patients with a history of HCC experienced HCC recurrence after DAA therapy, at mean time intervals ranging from 4 to 21 months. This result increased when going from European studies (23%, CI, 17–28%) to US studies (34%, CI, 30–38%), to Egyptian studies (37%, CI, 27–47%), and to Asian studies (33%, CI, 27–40%). Sixty-eight percent (CI, 45–91%) of recurrent HCCs developed within 6 months of follow-up since DAA treatment, among the eight studies providing stratified data. Among the studies providing head-to-head comparisons, the HCC recurrence risk was significantly lower after DAA therapy than IFN (RR, 0.64; CI, 0.51–0.81), and after DAA therapy than no intervention (RR, 0.68; CI, 0.49–0.94). Conclusions: The recurrence of HCC after DAA is not negligible, being higher soon after the end of treatment and among non-European countries. DAA therapy seems to reduce the risk of HCC recurrence compared to an IFN regimen and no intervention.

scholarly journals Efficacy and safety of direct-acting antivirals for treatment of hepatitis C infected kidney transplant recipients; a meta-analysis

2017 ◽  
Vol 6 (2) ◽  
pp. 49-61
Author(s):  
Wisit Cheungpasitporn ◽  
Charat Thongprayoon ◽  
Karn Wijarnpreecha ◽  
Ankit Sakhuja ◽  
Wonngarm Kittanamongkolchai ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Kidney Transplant ◽  
Meta Analysis ◽  
Efficacy And Safety ◽  
Transplant Recipients ◽  
Direct Acting Antivirals ◽  
Kidney Transplant Recipients ◽  
Direct Acting
Sign in / Sign up

Export Citation Format

Share Document